UA104945C2 - Фармацевтична композиція лігандів рецепторів секретагогів гормону росту - Google Patents

Фармацевтична композиція лігандів рецепторів секретагогів гормону росту

Info

Publication number
UA104945C2
UA104945C2 UAA201211831A UAA201211831A UA104945C2 UA 104945 C2 UA104945 C2 UA 104945C2 UA A201211831 A UAA201211831 A UA A201211831A UA A201211831 A UAA201211831 A UA A201211831A UA 104945 C2 UA104945 C2 UA 104945C2
Authority
UA
Ukraine
Prior art keywords
ligands
pharmaceutical composition
present
compositions
secretagogues
Prior art date
Application number
UAA201211831A
Other languages
English (en)
Russian (ru)
Inventor
Чжен Сінь Дун
Цзюньдун ЧЖАН
Original Assignee
Іпсен Фарма С.А.С.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Іпсен Фарма С.А.С. filed Critical Іпсен Фарма С.А.С.
Publication of UA104945C2 publication Critical patent/UA104945C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Винахід стосується фармацевтичної композиції прозорого розчину, гелю або напівтвердої речовини, або суспензії, яка містить пептид відповідно до структури Н-Inp-D-Bal-D-Trp-Phe-Apc-NH, який діє як ліганд рецептора GHS, або його фармацевтично прийнятну сіль, в якій даний пептид утворює депо in situ після підшкірної або внутрішньом'язової ін'єкції суб'єкту, де фармацевтична композиція додатково містить ПЕГ і вказаний пептид знаходиться у вигляді памоатної солі.
UAA201211831A 2010-03-15 2011-03-14 Фармацевтична композиція лігандів рецепторів секретагогів гормону росту UA104945C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34029010P 2010-03-15 2010-03-15
PCT/US2011/028283 WO2011115871A1 (en) 2010-03-15 2011-03-14 Pharmaceutical compositions of growth hormone secretagogue receptor ligands

Publications (1)

Publication Number Publication Date
UA104945C2 true UA104945C2 (uk) 2014-03-25

Family

ID=44649531

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201211831A UA104945C2 (uk) 2010-03-15 2011-03-14 Фармацевтична композиція лігандів рецепторів секретагогів гормону росту

Country Status (14)

Country Link
US (2) US20130210751A1 (uk)
EP (1) EP2547351B1 (uk)
JP (2) JP5977225B2 (uk)
KR (1) KR101589191B1 (uk)
CN (1) CN102821775B (uk)
AU (1) AU2011227532B2 (uk)
BR (1) BR112012023303A2 (uk)
CA (1) CA2792866C (uk)
ES (1) ES2579941T3 (uk)
HK (1) HK1180599A1 (uk)
MX (1) MX343499B (uk)
RU (1) RU2523566C2 (uk)
UA (1) UA104945C2 (uk)
WO (1) WO2011115871A1 (uk)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041278A2 (en) * 2005-09-29 2007-04-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Composition and methods for stimulating gastrointestinal motility
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CA2687979C (en) 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
CN102665401A (zh) 2009-11-16 2012-09-12 益普生制药股份有限公司 黑皮质素受体配体的药物组合物
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB201012980D0 (en) * 2010-08-03 2010-09-15 Johnson Matthey Plc Membrane
TWI523863B (zh) 2012-11-01 2016-03-01 艾普森藥品公司 體抑素－多巴胺嵌合體類似物
US9777039B2 (en) 2012-11-01 2017-10-03 Ipsen Pharma S.A.S. Somatostatin analogs and dimers thereof
WO2015134567A1 (en) * 2014-03-04 2015-09-11 Rhythm Pharmaceuticals, Inc. Process for the liquid phase synthesis of h-inp-(d)bal-(d)trp-phe-apc-nh2, and pharmaceutically acceptable salts thereof
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CN113045625B (zh) * 2021-03-30 2023-11-07 成都诺和晟泰生物科技有限公司 作为生长激素促分泌素受体激动剂的多肽及其应用
CN113072617B (zh) * 2021-03-30 2023-08-08 成都诺和晟泰生物科技有限公司 一种多肽化合物及其应用
CN114805487B (zh) * 2022-06-07 2024-03-12 成都诺和晟泰生物科技有限公司 一种多肽化合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE267613T1 (de) * 1998-03-05 2004-06-15 Phares Pharm Res Nv Arzneimittel und deren verwendung
US20010020012A1 (en) * 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
MXPA03001771A (es) * 2000-08-30 2003-06-04 Pfizer Prod Inc Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
EP1694278A4 (en) * 2003-12-16 2009-08-12 Ipsen Pharma GLP-1 PHARMACEUTICAL COMPOSITIONS
US20080171700A1 (en) * 2004-04-07 2008-07-17 Gastrotech Pharma A/S Use Of Secretagogue For The Teatment Of Ghrelin Deficiency
GB0412866D0 (en) * 2004-06-09 2004-07-14 Novartis Ag Organic compounds
WO2007041278A2 (en) * 2005-09-29 2007-04-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Composition and methods for stimulating gastrointestinal motility
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
US20100227806A1 (en) * 2006-03-10 2010-09-09 Tulipano Giovanni Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment
JP2010505819A (ja) * 2006-10-05 2010-02-25 パナセア バイオテック リミテッド デポ型注射剤組成物とその調製方法
TW200916113A (en) * 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
JP5350467B2 (ja) * 2008-05-14 2013-11-27 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ ソマトスタチン−ドーパミンコンジュゲートの医薬組成物
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
PT2323623T (pt) * 2008-08-12 2016-11-04 Novartis Ag Composições farmacêuticas
IE20100174A1 (en) * 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides

Also Published As

Publication number Publication date
JP5977225B2 (ja) 2016-08-24
JP2013522301A (ja) 2013-06-13
JP2015163620A (ja) 2015-09-10
EP2547351A1 (en) 2013-01-23
KR101589191B1 (ko) 2016-01-27
ES2579941T3 (es) 2016-08-17
CN102821775A (zh) 2012-12-12
RU2012143747A (ru) 2014-04-20
BR112012023303A2 (pt) 2020-08-25
WO2011115871A1 (en) 2011-09-22
KR20130004334A (ko) 2013-01-09
EP2547351B1 (en) 2016-04-27
RU2523566C2 (ru) 2014-07-20
US20130210751A1 (en) 2013-08-15
US20160220637A1 (en) 2016-08-04
AU2011227532B2 (en) 2014-03-13
MX343499B (es) 2016-11-08
CA2792866A1 (en) 2011-09-22
AU2011227532A1 (en) 2012-09-13
EP2547351A4 (en) 2013-08-28
MX2012010691A (es) 2013-01-25
CA2792866C (en) 2016-05-31
CN102821775B (zh) 2014-10-22
HK1180599A1 (zh) 2013-10-25

Similar Documents

Publication Publication Date Title
UA104945C2 (uk) Фармацевтична композиція лігандів рецепторів секретагогів гормону росту
US20220160818A1 (en) Pharmaceutical compositions
WO2011054001A3 (en) Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
ES2515097T3 (es) Formulación de liberación sostenida que comprende un análogo de somatostatina
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
CA2660208A1 (en) Cyclic angiotensin analogs
FI3227675T3 (fi) Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
MX349162B (es) Sistemas de deposito que comprende glatiramer o una sal farmacologicamente aceptable del mismo.
JP2012067099A5 (uk)
WO2012054500A3 (en) Compositions for drug administration
JP2016516722A5 (uk)
ZA202202410B (en) Rna particles comprising polysarcosine
EA033590B1 (ru) Препараты с контролируемым высвобождением
TW201536346A (zh) 用於持續釋放蘭瑞肽之醫藥組成物
WO2009139855A3 (en) Pharmaceutical compositions of somatostatin-dopamine conjugates
US9987333B2 (en) Method for suppressing malignant tumor metastasis
RU2015119472A (ru) Терапевтическое средство для бокового амиотрофического склероза
WO2017082186A1 (ja) Ｎｐｒ－ａアゴニストの新規用途
EP3212219A1 (en) New indication for alpha-msh analogues
US20150157719A1 (en) Aqueous Gelling Compositions of Soluble Active Pharmaceutical Peptides Providing Modified Release
RU2018132694A (ru) Фармацевтическая композиция, включающая рекомбинантный гормон роста человека для лечения дефицита гормона роста
RU2017132449A (ru) Фармацевтические композиции ингибитора c1-эстеразы
CN1780635B (zh) 肝病的预防或治疗剂